Our Technology
Our technology is based on biocompatible dendritic core multi-shell nanocarriers. This technology was developed between 2002 and 2012 by Prof. Dr. Rainer Haag’s group at the University of Dortmund and the Free University of Berlin. The safety and efficiency of our technology has already been tested in vitro and in vivo.
As a platform technology, our carriers can be adapted to the needs of our customers and research partners. By adjusting the polar and non-polar areas of our carriers, we can, for example, improve the loading of a specific active ingredient and thus increase the solubility and bioavailability of the active ingredient.
DendroSol
DendroSol™ is a highly amphiphilic carrier that significantly improves the skin penetration of both lipophilic and hydrophilic drugs, especially those that are poorly soluble or highly lipophilic. It facilitates transport through the stratum corneum and, compared to conventional formulations, ensures higher concentrations of active ingredients in deeper skin layers. DendroSol™ is non-toxic and non-irritating and has been shown to be effective with substances such as doxorubicin, dexamethasone, sagopilone, nimodipine, Nile Red and rhodamine B.
DendroCarrier
DendroCarrier™ carriers selectively accumulate in tumour tissue and enable controlled, pH-dependent drug release within the tumour environment. This pH-sensitive technology, exclusively licensed by the Free University of Berlin, has already successfully encapsulated drugs such as nimodipine and doxorubicin. Initial animal studies show excellent biocompatibility.
DendroCore
DendroCore™ is a highly sulphated, multivalent preparation that acts as an effective heparin analogue with strong anti-inflammatory and antithrombotic properties. Its efficacy is based on strong binding to P- and L-selectins, which blocks the adhesion of leukocytes to inflamed tissue and thus interrupts an important step in the inflammatory cascade.
FAQ
Was ist ein CMS Nanocarrier(cluster)
Core multi-shell Carrier, wie DendroSol, bestehen aus einem polaren hochverzweigten Polyglycerin (hPG) Kern und mehreren apolaren/lipophilen und polaren/hydrophilen Schalen. Die äußerste polyethylenglycolbasierte (MPEG) Schale sorgt für die hohe Wasserlöslichkeit der Nanopartikel, in der inneren aliphatischen, ergo apolaren Schale, können sich lipophile/nicht-wasserlösliche Wirkstoffe anlagern, aber auch polare Wirkstoffe können von den CMS-Carriern transportiert werden. Die Carrier erhöhen somit die Löslichkeit von Wirkstoffen in wässrigen Medien und können diese an ihr Ziel bringen.
Beispielsweise können Nanocarrier Cluster von 30-130 nm Größe ausbilden. Diese akkumulieren aufgrund des EPR Effect (Enhanced penetration and retention) selektiv in Tumorgewebe wodurch Wirkstoffe gezielt an ihren Wirkort gebracht werden und dort z.B. durch die lokale pH-Änderung freigesetzt werden können.
Please contact us for further information about our technology.
DendroPharm is interested in collaborating with companies or academic research groups to develop new drugs and novel drug delivery systems.